Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1106]
News [2760]
Articles [185]
Editorials [9]
Conferences [110]
elearning [25]

ASCO 2026: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada
ASCO 2026: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )
1 Jun 2026

ASCO 2026: Latest in prostate cancer

Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel Merseburger
ASCO 2026: Latest in prostate cancer ( Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel Merseburger )
1 Jun 2026

177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC

Dr Pedro Barata - University Hospitals Seidman Cancer Center, Cleveland, USA
177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC ( Dr Pedro Barata - University Hospitals Seidman Cancer Center, Cleveland, USA )
1 Jun 2026

Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC

Dr David Pook - Monash Health, Melbourne, Australia
Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC ( Dr David Pook - Monash Health, Melbourne, Australia )
1 Jun 2026

miR371 shows promise as a surveillance biomarker for relapse in early-stage germ cell tumours

Dr Lucia Nappi - University of British Columbia, Vancouver, Canada
miR371 shows promise as a surveillance biomarker for relapse in early-stage germ cell tumours ( Dr Lucia Nappi - University of British Columbia, Vancouver, Canada )
31 May 2026

Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment

Dr Karen Mustian - Wilmot Cancer Institute, Rochester, USA
Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment ( Dr Karen Mustian - Wilmot Cancer Institute, Rochester, USA )
31 May 2026

Apalutamide plus ADT improves surgical outcomes in high-risk prostate cancer

Dr Adam Kibel - Dana-Farber Cancer Institute, Boston, USA
Apalutamide plus ADT improves surgical outcomes in high-risk prostate cancer ( Dr Adam Kibel - Dana-Farber Cancer Institute, Boston, USA )
31 May 2026

ASCO 2026: Latest updates in mRCC

Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke
ASCO 2026: Latest updates in mRCC ( Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke )
30 May 2026

Darolutamide shows less cognitive decline than enzalutamide in advanced prostate cancer

Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA
Darolutamide shows less cognitive decline than enzalutamide in advanced prostate cancer ( Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA )
30 May 2026

Combination therapeutic strategies for aRCC patients with bone metastases

Prof Stéphane Oudard and Dr Stefanie Zschäbitz
Combination therapeutic strategies for aRCC patients with bone metastases ( Prof Stéphane Oudard and Dr Stefanie Zschäbitz )
13 May 2026

Part 1: Why test?

Dr Elena Castro - Hospital Universitario 12 de Octubre, Madrid, Spain
Part 1: Why test? ( Dr Elena Castro - Hospital Universitario 12 de Octubre, Madrid, Spain )
5 May 2026

Part 2: How to get biopsies for testing?

Dr Lynda Corrigan and Dr Stephen Finn
Part 2: How to get biopsies for testing? ( Dr Lynda Corrigan and Dr Stephen Finn )
5 May 2026

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation